🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Small Intestine Cancer

AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840Phase 148 sites📍 Phoenix📍 Scottsdale📍 Duarte Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031Phase 21 site📍 Beijing Guangzhou JOYO Pharma Co., Ltd · Tests: JYP0015 A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors NCT06764771Phase 18 sites📍 Hackensack📍 Allentown📍 Germantown Bristol-Myers Squibb · Tests: BMS-986488, Adagrasib, Cetuximab, Nivolumab A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors NCT07145255Phase 1, Phase 27 sites📍 San Francisco📍 Grand Rapids📍 East Brunswick MBrace Therapeutics · Tests: ADC BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers NCT07060014Phase 12 sites📍 Houston📍 Houston The Methodist Hospital Research Institute · Tests: Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 6… A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations NCT07610798Phase 1, Phase 21 site📍 Guangzhou Shenzhen Ionova Life Sciences Co., Ltd. · Tests: INV-8989 A Phase 1 Study of IM-1617 in Participants With Advanced Cancer NCT07578571Phase 14 sites📍 New Haven📍 Sarasota📍 Boston Immunome, Inc. · Tests: IM-1617 A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) NCT05865002Phase 137 sites📍 Vijayawada📍 Visakhapatnam📍 Chandigarh Aurigene Discovery Technologies Limited · Tests: AUR107 A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors NCT06983743Phase 19 sites📍 Santa Rosa📍 Aurora📍 Sarasota Erasca, Inc. · Tests: ERAS-0015, ERAS-0015 in combination Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation NCT05288205Phase 1, Phase 227 sites📍 Hefei📍 Beijing📍 Beijing Allist Pharmaceuticals, Inc. · Tests: JAB-21822, JAB-3312 Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541Phase 117 sites📍 Sacramento📍 New Haven📍 Sarasota Revolution Medicines, Inc. · Tests: RMC-9805, RMC-6236 A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569Phase 114 sites📍 Orlando📍 Tampa📍 Boston Alterome Therapeutics, Inc. · Tests: ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors NCT07887971Phase 11 site📍 Miami Aktis Oncology, Inc. · Tests: [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) TT-702 in Patients With Advanced Solid Tumours. NCT05272709Phase 1, Phase 23 sites📍 London📍 Manchester📍 Southampton Cancer Research UK · Tests: TT-702, Anti-PD-1 and PD-L1 agent Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors NCT06218914Phase 118 sites📍 Duarte📍 Los Angeles📍 Newport Beach AstraZeneca · Tests: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors NCT07589205Phase 11 site📍 Tianjin Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tests: Drug: IBI3028 Evaluation of XYA02 in Patients With Advanced Solid Tumors NCT07670312Phase 1, Phase 25 sites📍 Sydney📍 Sydney📍 Melbourne XYone Therapeutics, Inc · Tests: XYA02 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers NCT04205968Phase 2536 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Fluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin, Leucovorin Calcium Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT07435038Phase 1, Phase 27 sites📍 Blacktown📍 Randwick📍 Sydney Betta Pharmaceuticals Co., Ltd. · Tests: BPI-572270 AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642Phase 17 sites📍 Scottsdale📍 Sarasota📍 Chicago Avacta Life Sciences Ltd · Tests: AVA6103 Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer. NCT06227728n/a2 sites📍 Ho Chi Minh City📍 Ho Chi Minh City Gene Solutions Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537Phase 19 sites📍 New Haven📍 Baltimore📍 Boston Revolution Medicines, Inc. · Tests: RMC-5127, daraxonrasib, cetuximab SMP-3124LP in Adults With Advanced Solid Tumors NCT06526819Phase 1, Phase 213 sites📍 Los Angeles📍 San Francisco📍 Denver Sumitomo Pharma America, Inc. · Tests: SMP3124LP A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation NCT07458347Phase 19 sites📍 Los Angeles📍 Sarasota📍 Tampa Kestrel Therapeutics, Inc. · Tests: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy